Iterum Therapeutics plc.
ITRM.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing differentiated anti-infectives to address the unmet needs of multi-drug resistant pathogens. The company's lead product candidate is sulopenem, a novel penem antibiotic for the treatment of infections cause...Show More
Better Health for All
0
No evidence available to assess Iterum Therapeutics plc on Better Health for All.
Fair Money & Economic Opportunity
0
Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing anti-infectives, such as ORLYNVAH™ (oral sulopenem) for uncomplicated urinary tract infections. The company received FDA approval for ORLYNVAH™ in October 2024 and plans a commercial launch in Q4 2025.
1
Its financial summary for Q1 2025 reported a net loss of $4.9 million.
2
The provided articles do not contain any evidence that Iterum Therapeutics plc offers lending, deposit services, or other financial products to consumers or businesses. Therefore, all KPIs related to fair money and economic opportunity are not applicable to the company's core business activities.
Fair Pay & Worker Respect
0
Iterum Therapeutics plc has 9 full-time employees as of January 31, 2025.
1
None of these employees are represented by labor unions or covered by collective bargaining agreements.
2
The company considers its employee relations to be good.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Iterum Therapeutics plc on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-10
Iterum Therapeutics plc has a comprehensive whistleblower policy that applies worldwide, allows for anonymous reporting via a secure web form and a toll-free number, and explicitly prohibits retaliation.
1
This policy is communicated annually to all employees, officers, and directors.
2
Four out of five current directors are deemed independent by the board, representing 80% of the board.
3
The company has a Code of Business Conduct and Ethics that prohibits bribes and kickbacks and states compliance with the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act.
4
This Code was last reviewed in April 2022 and distributed annually since 2016, but there is no evidence of training frequency or effectiveness metrics.
5
Kind to Animals
-60
Iterum Therapeutics plc uses animal models for product testing, specifically mentioning murine efficacy studies of Sulopenem against Bacillus anthracis.
1
There is no evidence that the company employs non-animal testing methods, even though the FDA's Modernization Act 2.0 in December 2022 authorized reliance on alternative non-clinical tests.
2
The company's preclinical tests are conducted in compliance with GLP regulations and the United States Department of Agriculture’s Animal Welfare Act.
3
However, no specific company policy to reduce or ban animal testing, or to prioritize alternatives beyond legal mandates, is mentioned.
4
No quantitative data on the volume of animals used in testing is provided.
5
No War, No Weapons
0
Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing anti-infectives, such as the antibiotic ORLYNVAH™ for urinary tract infections.
1
The provided articles consistently describe the company's core business as pharmaceutical development and commercialization, with no mention of any involvement in arms manufacturing, military contracts, or conflict facilitation. There is no evidence of revenue from arms or defense contracts,
2
R&D investment in dual-use technologies with military applications,
3
sales to embargoed regimes,
4
or any other activities related to the defense industry or conflict. Therefore, all KPIs are scored as N/A, indicating no defense or arms-related activities in the company's core business or operations.
Planet-Friendly Business
0
Iterum Therapeutics plc has set a short-term target for 2024-2025 to set Science-Based Targets (SBTs) and to consume 100% of its electricity from renewable energy plants.
1
The company also has a medium-term target for 2026-2029 to reduce CO2 emissions by 50% per unit produced compared to 2021, and to maintain 100% recycled material use in the production of its final product.
2
A long-term target is to maintain net-zero greenhouse gas emissions across the value chain by 2030-2050.
3
The company aims for "Zero-incidents" with legal non-compliance and major financial penalties in the short-term (2024-2025).
4
Iterum Therapeutics has verified greenhouse gas emissions and holds ISO 14064-1:2018 verification for its GHG emissions.
5
It has also achieved ISO 14001:2015 Environmental Management System certification and ISO 50001:2018 Energy Management System certification.
6
The company was awarded Platinum category in the Latvian Sustainability Index in 2024, Gold in 2023, and Silver in 2022.
7
Respect for Cultures & Communities
0
No evidence available to assess Iterum Therapeutics plc on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Iterum Therapeutics plc on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
The provided articles, which include financial reports (10-Q filings) and governance documents, do not contain any quantitative data or specific information related to Iterum Therapeutics plc's waste management practices, product recyclability, packaging sustainability, or any other metrics relevant to the 'Zero Waste & Sustainable Products' ethical value.
1
The documents primarily focus on the company's financial performance, clinical trials, regulatory matters, and corporate governance.